Physician profile
Joe D Davison
NPI 1891803771
$3,708.79
in general payments reported to CMS, 2019-2025
38 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $292 · 2021: $846 · 2022: $500 · 2023: $195 · 2024: $603 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $435.10 | 2019-2025 | Evenity, Prolia |
| Pfizer INC. | $419.77 | 2019-2025 | |
| Abbvie INC. | $409.35 | 2019-2025 | Ubrelvy |
| Novo Nordisk INC | $343.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $335.10 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Medtronic, INC. | $190.93 | 2021-2025 | Intellis Adaptivestim, Symplicity G3 |
| Lilly USA, LLC | $136.83 | 2019-2025 | Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $124.69 | 2019-2022 | |
| Amarin Pharma, INC. | $105.95 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.44 | 2022-2025 | Jardiance, Ofev |
| Sumitomo Pharma America, INC. | $101.76 | 2023-2025 | Gemtesa |
| Allergan, INC. | $82.83 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $81.98 | 2019-2021 | |
| Astellas Pharma US INC | $71.83 | 2019-2021 | |
| Grifols USA, LLC | $69.87 | 2024-2025 | Prolastin-C Liquid |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Davison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.